Financial Performance - The company reported revenue of approximately HKD 190,330,000 for the six months ended December 31, 2023, a decrease of 53.0% compared to HKD 405,080,000 for the same period in 2022[4]. - Gross profit for the same period was approximately HKD 16,795,000, with a gross margin of 8.8%, down from HKD 26,691,000 and a gross margin of 6.6% in the previous year, representing a decrease of 37.1%[4]. - The company recorded a loss attributable to owners of approximately HKD 6,734,000, an improvement from a loss of HKD 7,831,000 in the same period last year[5]. - Revenue from customers in China for the six months ended December 31, 2023, was approximately HKD 190,330,000, compared to HKD 387,331,000 for the same period in 2022, indicating a significant decrease[70]. - The total comprehensive loss for the six months ended December 31, 2023, was HKD 4,030,000, compared to a loss of HKD 5,308,000 for the same period in 2022, indicating an improvement of 24%[73][75]. Expenses and Costs - Administrative expenses decreased by 10.9% to approximately HKD 9,412,000 from HKD 10,566,000 in the prior period, primarily due to enhanced cost control measures[5]. - The total employee cost, including director remuneration, was approximately HKD 3,591,000, a decrease of 59.7% compared to HKD 8,920,000 for the same period in 2022[35]. - Central administrative expenses for the six months ended December 31, 2023, were HKD 2,101,000, down from HKD 3,501,000 in the same period of 2022, a reduction of 40%[73][75]. - The financial costs for the six months ended December 31, 2023, were HKD 8,829,000, compared to HKD 8,424,000 in the same period of 2022, showing an increase of 4.8%[73][75]. Assets and Liabilities - As of December 31, 2023, the company's current liabilities net value was approximately HKD 45,586,000, compared to HKD 29,657,000 as of June 30, 2023[6]. - The current ratio as of December 31, 2023, was approximately 0.79, slightly down from 0.81 as of June 30, 2023[6]. - The company's non-current assets increased to HKD 131,647 from HKD 111,059 as of June 30, 2023, reflecting a growth of 18.5%[53]. - The aging analysis of accounts payable shows a total of HKD 79,474,000 as of December 31, 2023, compared to HKD 63,945,000 as of June 30, 2023, indicating an increase in liabilities[87]. Strategic Plans and Investments - The company plans to continue strategic acquisitions to capture new opportunities in the Chinese market and strengthen its revenue and profit base[14]. - The company is actively seeking growth projects for acquisition or investment and is in discussions with multiple parties regarding these opportunities[14]. - The company has implemented measures to improve its financial situation, including financing from the ultimate holding company and ongoing discussions with potential investors[14]. - The group has no major investment or capital asset plans, aside from capital expenditures for operations, which will be funded by internal cash flow and borrowings[20]. Governance and Management - The company has adopted corporate governance practices in accordance with the listing rules, although it did not separate the roles of Chairman and CEO during the review period[40]. - The audit committee, consisting of two independent non-executive directors, reviewed the unaudited interim financial results for the six months ending December 31, 2023[47]. - The company is in the process of identifying suitable candidates to fill the vacancy left by the resignation of an independent non-executive director on August 9, 2023[41]. Shareholder Information - Major shareholders include Mr. Lin Qingqu, who holds 268,072,400 shares, representing approximately 156.33%[25]. - Onward Global Investments holds 12,863,500 shares, representing approximately 7.50%[25]. - Fair Concourse Limited holds 14,127,040 shares, representing approximately 8.24%[27]. Cash Flow and Financing - Cash generated from operating activities increased to HKD 24,665, compared to HKD 11,866 in 2022, marking a 107.5% increase[58]. - The company has secured loans of approximately HKD 4,641,000 and has access to additional financing of approximately HKD 65,359,000 from its ultimate holding company, Wei Jun Investment Fund[64]. - The board believes that the group will have sufficient cash resources to meet its operational funding and other financing needs for the next twelve months[65]. Employee and Director Remuneration - Total remuneration for directors and key management personnel for the six months ended December 31, 2023, was HKD 262,000, down from HKD 518,000 in the previous year[95]. - The group had a total of 130 employees as of December 31, 2023, up from 128 employees as of June 30, 2023[35].
玮俊生物科技(00660) - 2024 - 中期财报